A startup born in the halls of the University of Louisville has been acquired by biotech company Orgenesis, Inc. The company, Koligo Therapeutics Inc., develops cell-therapy technologies using a patient’s own cells. The deal is worth about $15 million.
Koligo makes several intriguing products. One therapy, called Kyslecel, treats chronic and recurrent acute pancreatitis. In that therapy, doctors remove a diseased pancreas, send it to Koligo where scientists extract cells, which are returned to the body to produce insulin needed to regulate blood sugar. In the future, surgeons will be able to use another Koligo product, called 3D-V, to deliver the cells via bioprinting technology, also developed at UofL.